S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.58 HKD 3.77%
Market Cap: 10.6B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Other Long-Term Assets
HK$216.2m
CAGR 3-Years
33%
CAGR 5-Years
-6%
CAGR 10-Years
-6%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Other Long-Term Assets
HK$892m
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
11%
U
United Laboratories International Holdings Ltd
HKEX:3933
Other Long-Term Assets
ÂĄ87.8m
CAGR 3-Years
-9%
CAGR 5-Years
-22%
CAGR 10-Years
-13%
Sino Biopharmaceutical Ltd
HKEX:1177
Other Long-Term Assets
ÂĄ989.3m
CAGR 3-Years
-39%
CAGR 5-Years
-12%
CAGR 10-Years
6%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Other Long-Term Assets
HK$6.1B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Other Long-Term Assets
$37.3m
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
62%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
10.6B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
5.42 HKD
Undervaluation 34%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Other Long-Term Assets?
Other Long-Term Assets
216.2m HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Other Long-Term Assets amounts to 216.2m HKD.

What is SSY Group Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-6%

Over the last year, the Other Long-Term Assets growth was 49%. The average annual Other Long-Term Assets growth rates for SSY Group Ltd have been 33% over the past three years , -6% over the past five years , and -6% over the past ten years .

Back to Top